Bacopa monnieri vs Dihexa
Side-by-side comparison of Bacopa monnieri and Dihexa: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Bacopa monnieri
Dihexa
Bacopa monnieri
Bacopa monnieri is a creeping, succulent-leaved aquatic perennial that grows in wetlands, bogs, and rice paddies across the Indian subcontinent, Southeast Asia, northern Australia, and the southern United States. Known…
No vendor price on file.
Full Bacopa monnieri profileDihexa
Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models…
Lowest listed price: $79.99 across 3 listings
Full Dihexa profileSide-by-side comparison
| Attribute | Bacopa monnieri | Dihexa |
|---|---|---|
| Category | Nootropic Adaptogen | Nootropics |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | Bacopa monnieri's cognitive effects emerge from at least six convergent molecular mechanisms that span neurotransmitter modulation, trophic-factor expression, structural plasticity, antioxidant defense, vascular regulation, and receptor-level anxiolysis. No… | Dihexa is a small-molecule analog derived from angiotensin IV (AngIV). It retains the Tyr-Ile core of Nle1-AngIV, with an N-terminal hexanoic acid cap and a C-terminal 6-aminohexanoic amide that give it metabolic stability and blood-brain-barrier penetration.… |
| Half-Life | — | Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. |
| Typical Dose Range | — | 5 to 40 mg oral per day (anecdotal range; no established human dose) |
| Dosing Frequency | — | Once daily (oral), typically in the morning |
| Administration | — | Oral, Intranasal, Subcutaneous |
| Side Effects | Bacopa monnieri's side-effect profile is dominated by gastrointestinal symptoms, which occur in 20-30% of users at therapeutic doses and represent the primary reason users discontinue the compound. Mechanistically, the GI effects appear to reflect Bacopa's… | No controlled human safety data. Anecdotal user reports include headache, fatigue, irritability or anxiety, insomnia, and vivid dreams, usually at higher doses. The most serious concern is theoretical rather than reported: because dihexa acts on the HGF/c-Met… |
| Molecular Weight | — | 504.7 g/mol |
| Common Vial Sizes | — | 50mg, 100mg |
Price tracking
Bacopa monnieri: potential benefits
- No structured benefit list published.
Dihexa: potential benefits
- Synaptogenesis: formation of new dendritic spines and functional synapses (preclinical)
- Memory and spatial-learning support in rodent models
- Potential research application in Alzheimer's and other neurodegenerative disease models
- HGF/c-Met and PI3K/Akt-linked neuroplasticity (mechanism proposed; key paper retracted)
Frequently asked
What's the difference between Bacopa monnieri and Dihexa?
Bacopa monnieri is a nootropic adaptogen that bacopa monnieri's cognitive effects emerge from at least six convergent molecular mechanisms that span neurotransmitter modulation, trophic-factor expression, structural…. Dihexa is a nootropics that dihexa is a small-molecule analog derived from angiotensin iv (angiv). it retains the tyr-ile core of nle1-angiv, with an n-terminal hexanoic acid cap and a c-terminal…. The two differ in mechanism, half-life (not reported vs Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.), and typical dose range.
Which has the longer half-life, Bacopa monnieri or Dihexa?
Bacopa monnieri has a half-life of not reported. Dihexa has a half-life of Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Can you stack Bacopa monnieri and Dihexa?
Stacking depends on mechanism overlap, safety profile, and goals. Bacopa monnieri and Dihexa should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Bacopa monnieri or Dihexa
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.